Astra Zeneca

In 2023, AstraZeneca reported total carbon emissions of approximately 6,000,000 kg CO2e across its operations. This includes 180,898,000 kg CO2e from Scope 1 emissions, primarily from direct operations, and 19,940,000 kg CO2e from Scope 2 emissions, which are associated with purchased electricity. The company also disclosed significant Scope 3 emissions, amounting to about 5,917,160,000 kg CO2e, which encompass indirect emissions from the entire value chain. AstraZeneca has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by FY2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 98% by FY2026 from a 2015 baseline. Additionally, it aims to cut Scope 3 emissions by 50% by FY2030 from a 2019 baseline. Specific targets within this framework include an 80% reduction in emissions from fuel and energy-related activities, upstream leased assets, and downstream leased assets by FY2030, as well as a 95% reduction in emissions from the use of sold products. AstraZeneca is also committed to ensuring that 95% of its suppliers by spend for purchased goods and services and capital goods, and 50% of suppliers for upstream transportation and distribution and business travel, will have science-based targets by FY2025. These initiatives reflect AstraZeneca's dedication to sustainability and its proactive approach to addressing climate change within the pharmaceutical industry.